Clinical trial
Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
NCT03496012 · Biogen, Industry · Completed
Key facts
| NCT number | NCT03496012 |
|---|---|
| Title | Efficacy and Safety of BIIB111 for the Treatment of Choroideremia |
| Official title | A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1) |
| Acronym | STAR |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Choroideremia |
| Intervention type | Genetic |
| Interventions | BIIB111 |
| Enrollment | 169 |
| Start date | Dec 11, 2017 |
| Primary completion | Dec 1, 2020 |
| Completion | Dec 1, 2020 |
| First posted | Apr 12, 2018 |
| Last update posted | Dec 7, 2023 |
| Countries | Canada, Denmark, Finland, France, Germany, Netherlands, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: